Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -0.59% | 180.53% | |||
| Total Other Revenue | -0.59% | -15.45% | |||
| Total Revenue | -0.59% | 37.32% | |||
| Cost of Revenue | -0.59% | -26.57% | |||
| Gross Profit | 0.59% | 40.54% | |||
| SG&A Expenses | -0.59% | -18.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.59% | -24.22% | |||
| Operating Income | 0.59% | 33.15% | |||
| Income Before Tax | 0.59% | 29.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.59% | 29.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.59% | 29.14% | |||
| EBIT | 0.59% | 33.15% | |||
| EBITDA | 0.59% | 33.41% | |||
| EPS Basic | 0.57% | 30.35% | |||
| Normalized Basic EPS | 0.65% | 30.33% | |||
| EPS Diluted | 0.65% | 30.01% | |||
| Normalized Diluted EPS | 0.65% | 30.33% | |||
| Average Basic Shares Outstanding | 0.00% | 1.71% | |||
| Average Diluted Shares Outstanding | 0.00% | 1.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||